Abstract 859PD
Background
Improving NACT response rate in pts with OC could lead to increased complete resection rate (CC0) at IDS and better survival. Bevacizumab has been shown to increase response rate to chemotherapy both in first-line (ICON7) and in relapse (OCEANS and AURELIA). Due to concerns about bevacizumab impact on IDS wound healing, the safety and efficacy of nintedanib, an orally available anti-VEGF/PDGFR/FGFR tyrosine kinase inhibitor with a short half-life was explored in the neo-adjuvant setting.
Methods
All patients underwent laparoscopy and their disease was considered as unresectable (impossibility to achieve CC0 at primary surgery). Eligible patients were randomized (2:1) to receive 3 cycles of NACT before IDS and 3 cycles of chemotherapy after IDS with carboplatin + paclitaxel and nintedanib or placebo (at cycle 1&2, 5&6 and at maintenance therapy as single agent during 2 years). The aim of IDS was to achieve CC0. Surgical complications were scored according to Clavien Dindo classification.
Results
A total of 188 patients were included and 121 (64%) patients underwent IDS (49 in placebo arm and 72 in experimental arm). Pts characteristics are well balanced between both arms. No significant difference was observed between the placebo and the nintedanib arm in terms of operating procedure duration (360 vs 330 minutes) and per-operative (18 vs 13%) complications. Bleeding (2 vs 9% of the pts), blood losses (500 vs 675 ml), and transfusion rate (12 vs 26% of the pts) were slightly less frequent in the placebo arm. Around half of the patients experienced at least one postoperative complication: 53% versus 47% in the placebo and nintedanib arm respectively. They were mostly of grade I-II (86% grade I-II, 14% grade III-IVa) with no significant difference between the two arms in type and grade of postoperative complications.
Conclusions
Compare to placebo, the addition of the anti-VEGF nintedanib to neo-adjuvant chemotherapy did not significantly increase the rate of per-operative and post-operative complications of the interval debulking surgery.
Clinical trial identification
NCT01583322
Legal entity responsible for the study
ARCAGY-GINECO
Funding
Boehringer Ingelheim
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
The predictive value of the CA-125 modeled kinetic parameter KELIM is validated in 3 independent datasets (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/GCIG trials)
Presenter: Benoit MP You
Session: Gynaecological cancers
Resources:
Abstract
Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers
Presenter: Ignace Vergote
Session: Gynaecological cancers
Resources:
Abstract
Presentation
Webcast
Principal results of the cancer of the ovary abiraterone trial (CORAL): A phase II study of abiraterone in patients with recurrent epithelial ovarian cancer (CRUKE/12/052)
Presenter: Susana Banerjee
Session: Gynaecological cancers
Resources:
Abstract
Presentation
Webcast
Invited discussant abstracts 859PD, 860PD and LBA35
Presenter: Ignace Vergote
Session: Gynaecological cancers
Resources:
Presentation
Webcast
Invited discussant abstract 856O and LBA33
Presenter: Domenica Lorusso
Session: Gynaecological cancers
Resources:
Presentation
Webcast
Invited discussant 857PD. 858PD and LBA34
Presenter: Florence Joly
Session: Gynaecological cancers
Resources:
Presentation
Webcast
Complete resection rate at interval debulking surgery after bevacizumab containing neoadjuvant therapy: primary objective of the ANTHALYA trial
Presenter: Roman Rouzier
Session: Gynaecological cancers
Resources:
Abstract
Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)
Presenter: Rebecca Kristeleit
Session: Gynaecological cancers
Resources:
Abstract
Presentation
Webcast
A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm+ OvCa)
Presenter: Jung-Min Lee
Session: Gynaecological cancers
Resources:
Abstract
A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA)
Presenter: Jasgit Sachdev
Session: Gynaecological cancers
Resources:
Abstract